Brief Summary
The study’s purpose is to understand the appearance of your prostate-specific membrane antigen (PSMA) PET scan after you take 14 days of treatment with a drug called dasatinib alone or in combination with anti-testosterone drug call darolutamide.
Who is it for? You may be eligible to join this study if you have metastatic prostatea walnut-shaped gland in the male reproductive system that is responsible for producing semen - a bodily fluid that acts as a vessel for sperm transport during ejaculation cancera disease where abnormal cells split without control and spread to other nearby body tissue and/or organs and had a recent PSMA scan showing low PSMA uptake
Study Details:
Participants will receive dasatinib 100 mg daily or dasatinib 100 mg daily and darolutamide 600 mg twice daily for 14 days. They will undergo another PSMA PET scan after 14 days. Participants will be followed up on day 7 of treatment and 30 days after treatment.
It is hoped that this research will provide insight into the mechanism of PSMA expression in advancedat a late stage, far along prostate cancer.
Intervention / Treatment
- Drug: Dasatinib
- Drug: Darolutamide
Inclusion Criteria
- Male, aged 18 years or older
- Pathologically confirmed adenocarcinomacancer arising from mucus-producing glands in organs of prostate or a clinical presentation consistent with prostate cancer
- Metastatic castrate resistant prostate cancer previously confirmed on 68Ga-PSMA-11 and 18F-FDG imagingtests that create detailed images of areas inside the body to be inadequate for future PSMA-directed theranostic treatment by a nuclear medicinea specialised area of radiology that involves the use of radioactive substances in the diagnosis and treatment of disease physician based on FDG-discordance (FDG-positive, PSMA-negative sites of disease) OR low PSMA SUV values within 2 weeks of starting study drug
- Adequate hematologic and organ function within 14 days before the first study treatment
- Castrate levels of testosterone < 1.7 ng/ml
- Provision of written informed consenta process in which a patient receives detailed information about a procedure or treatment, including its potential risks, benefits, and alternatives. The patient then has the opportunity to understand the information and voluntarily agree to the procedure or treatment..